Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,530,361 papers from all fields of science
Search
Sign In
Create Free Account
zolimomab aritox
Known as:
CD5-Immunoconjugate
, Anti-CD5 T-Lymphocyte Immunotoxin
, Anti-CD5 MoAb
Expand
An immunotoxin consisting of a murine anti-CD5 monoclonal antibody conjugated to the ricin A chain. The anti-CD5 monoclonal antibody component binds…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Narrower (2)
H65-RTA
XomaZyme-H65
Broader (2)
Monoclonal Antibodies
Ricin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1997
Highly Cited
1997
Mechanisms of T cell‐induced glomerular injury in anti‐glomeruler basement membrane (GBM) glomerulonephritis in rats
X. R. Huang
,
P. Tipping
,
+4 authors
S. Holdsworth
Clinical and Experimental Immunology
1997
Corpus ID: 12270780
The effector mechanisms of T cell‐dependent acute glomerular injury were studied in autologous phase anti‐GBM glomerulonephritis…
Expand
1995
1995
Anti CD5 Sustains the Proliferative Response of IgM‐Activated Human CD5+B Cells
C. Jamin
,
M. Dueymes
,
P. Lydyard
,
P. Youinou
Scandinavian Journal of Immunology
1995
Corpus ID: 1430702
The CD5 molecule is expressed by most T cells but it is present on a minor B cell subset. Whilst several studies have provided…
Expand
1992
1992
Reduction of graft‐versus‐host reactivity after small bowel transplantation: ex vivo treatment of intestinal allografts with an anti‐T cell immunotoxin
C. I. Clark
,
G. J. Smith
,
+4 authors
R. Wood
Clinical and Experimental Immunology
1992
Corpus ID: 46670547
A specific T lymphocyte immunotoxin was used to pre‐treat small bowel grafts in an attempt to prevent graft‐versus‐host (GVH…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE